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To the Editor, 26 
Cat-scratch disease (CSD) is a frequent worldwide zoonosis caused by Bartonella henselae 27 
and characterized by regional lymphadenopathy and often fever and malaise. The detection of 28 
B. henselae DNA by polymerase chain reaction (PCR) is considered the “gold standard” for 29 
diagnosis, but requires invasive procedures to obtain lymph node or pus specimens [1]. Thus, 30 
diagnosis relies on indirect serologic testing with immunofluorescence assay (IFA), which is 31 
limited by subjective interpretation, elaborate test procedures with a low throughput, and 32 
relatively low sensitivity (IgM-IFA: 54%-72% [2, 3]; IgG-IFA: 62%-85% [2]). As an 33 
alternative to IFA, several enzyme-linked immunosorbent assays (ELISAs) have been 34 
developed with various B. henselae-specific antigens: whole-cell proteins, water-insoluble 35 
protein, recombinant 17-kDa protein, GroEL, outer membrane protein, and N-lauroyl-36 
sarcosine-soluble protein (reviewed in Supplementary Material, Table S1). However, the 37 
sensitivity of most of these ELISAs was limited in PCR-positive CSD patients 38 
(Supplementary Material, Table S1). Interestingly, an IgM-ELISA using refined N-lauroyl-39 
sarcosine-insoluble protein (sarcosine-insoluble protein) showed improved sensitivity (83%) 40 
in CSD patients diagnosed by IgM-IFA [3]. 41 
 42 
Here, we compared diagnostic performance of new in-house assays using sarcosine-insoluble 43 
B. henselae antigens, such as IgM-ELISA, IgG-ELISA, and IgM/IgG/IgA-ELISA (“screening 44 
test”), to conventional IgM-IFA and IgG-IFA in a unique cohort of patients with CSD 45 
confirmed by PCR in lymph node or pus specimens, and in a clinically relevant control group. 46 
 47 
Twenty-five patients of a previous cohort [4] with a positive B. henselae-specific PCR result 48 
from lymph node or pus specimens and additional sera stored at −20°C for further testing 49 
were included. Control samples derived from a control cohort of a previous study [1] 50 
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consisting of 23 blood donors from Zurich. The local ethics committee approved the protocol 51 
for this study (2017-01421). 52 
For the ELISA, the sarcosine-insoluble protein was prepared from B. henselae reference strain 53 
(ATCC 49882) cultures on chocolate agar plates as described previously by Otsuyama et al. 54 
(antigen IV) [3]. Western blot analysis using IgM-IFA- and IgG-IFA-positive sera confirmed 55 
a band in the region of 8-10 kDa for sarcosine-insoluble proteins of B. henselae, and a 56 
complete lack of nonspecific reactions with IFA-negative sera (Supplementary material, 57 
Figure S1). The ELISAs were performed as described previously [3], with some 58 
modifications. In brief, 120 µl of antigen diluted in 50 mM carbonate-bicarbonate buffer (pH 59 
9.2) (IgM-ELISA and IgG-ELISA, 1:80; IgM/IgG/IgA-ELISA, 1:100) were coated on 96-60 
well half-area polystyrene plates (Sigma, St. Louis, MO, USA) o/n at 4°C. After blocking 61 
with PBS/5% skim milk/0.1% Tween 20 for 4 h at RT, 110 µl of sample diluted in PBS/0.1% 62 
Tween 20 (PBS-T) (test sera, 1:100; control sera, 1:100, 1:200, 1:400, and 1:800) were 63 
incubated in duplicate for 1 hour at 37°C. For IgM-ELISA, samples were diluted in anti-64 
human IgG solution (1:10; Virion\Serion, Würzburg, Germany) followed by PBS-T (test sera, 65 
1:10; control sera, 1:2, 1:4, 1:8, 1:16; final dilution: test sera, 1:100; control sera, 1:20, 1:40, 66 
1:80 and 1:160). Goat anti-human peroxidase detection antibodies (IgM, IgM-ELISA; IgG, 67 
IgG-ELISA; polyvalent Igs [G, A, M], IgM/IgG/IgA-ELISA; all Sigma) were diluted in PBS-68 
T (IgM-ELISA, 1:500; IgG-ELISA and IgM/IgG/IgA-ELISA, 1:1,000), added, and binding 69 
measured using o-phenylendiamine (Sigma) as optical density (OD) at 490 nm. IgM-IFA- and 70 
IgG-IFA-positive sera were used to determine the arbitrary units (AU) of anti-B. henselae 71 
antibodies (Supplementary material, Figure S2). 72 
Detection of anti-B. henselae antibodies by IFA was performed as described previously [2] 73 
with commercial slides with host cell-free agar-derived B. henselae for IgM (MRL 74 
Diagnostics, Cypress, CA, USA) using a cutoff of 1:20, and with commercial slides with Vero 75 
cell-associated B. henselae for IgG (MRL Diagnostics) using a cutoff of 1:256. 76 
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The best cutoff of the ELISA in differentiating between PCR-positive CSD patients and 77 
control subjects was defined as the optimal threshold that maximized the distance to the 78 
identity (diagonal) line in the receiver operating characteristic (ROC) curve according to 79 
Youden J statistic. Area under the ROC curve (AUC) differences were calculated using the 80 
DeLong test. All reported p-values are 2-tailed with statistical significance defined as p-value 81 
<0.05. Data were analyzed using the R software environment (version 3.6.0). 82 
 83 
The IgM-ELISA, IgG-ELISA, and IgM/IgG/IgA-ELISA yielded positive results in 24 (96%), 84 
18 (72%), and 19 (76%) of PCR-positive CSD patients, using the defined optimal cutoffs of 85 
0.10 AU, 1.00 AU and 0.57 AU, respectively (Figure 1A-C). Control samples with positive 86 
results were found by IgM-ELISA in 2 (9%), IgG-ELISA in 8 (35%), and IgM/IgG/IgA-87 
ELISA in 5 (22%) cases. Thus, the diagnostic odds ratio was significantly higher for IgM-88 
ELISA than for IgG-ELISA (p<0.01) and IgM/IgG/IgA-ELISA (p<0.01) (Supplementary 89 
material, Table S2). Compared to IFA, the IgM-ELISA showed a higher sensitivity with 90 
0.96 (95% CI, 0.80-0.99) than IgM-IFA (0.88, 95% CI, 0.70-0.96; p=0.61) and IgG-IFA 91 
(0.84, 95% CI, 0.65-0.94; p=0.35). In contrast to IgM-ELISA with 2 (9%) false-positive 92 
results, the specificities of IFAs were 100% (Figure 1D-E). Three (12%) CSD patients were 93 
IgM-positive but IgG-negative (ELISA and IFA), whereas only 1 (4%) patient was IgG-94 
positive but IgM-negative (ELISA and IFA). Overall, the AUC was better for IgM-ELISA 95 
(0.96, 95% CI, 0.91-1.00) than IgM-IFA (0.94, 95% CI, 0.88-1.00; p=0.41) and IgG-IFA 96 
(0.92, 95% CI 0.84-1.00; p=0.44) (Figure 1F). 97 
 98 
In conclusion, we corroborate previous findings about the IgM-ELISA using sarcosine-99 
insoluble B. henselae antigen [3] in a more relevant cohort of PCR-confirmed CSD patients. 100 
This IgM-ELISA is indeed a sensitive (96%) and specific (91%) test for the serodiagnosis of 101 
B. henselae infection. IgM can be detected up to 3 months following B. henselae infection [2] 102 
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and enables diagnosis prior to a seroconversion of IgG (12%). A limitation of the study is the 103 
small control group and that we did not test for cross-reactivity of IgM antibodies, as it has 104 
previously been described [1, 5]. The IgM-ELISA may overcome IFA in the routine diagnosis 105 
of CSD due to its objective, automated, and high-throughput analyses in addition to the 106 





Author contributions 111 
J.W. had full access to all of the data in the study and takes responsibility for the integrity of 112 
the data and the accuracy of the data analysis. 113 
Study concept and design: all authors; 114 
Acquisition of data: J.W., P.M.M.S., R.Z.; 115 
Analysis and interpretation of data: all authors; 116 
Drafting of the manuscript: P.M.M.S.; 117 
Critical revision of the manuscript for important intellectual content: all authors; 118 
Study supervision: C.B. 119 
 120 




We thank all former patients and controls that volunteered in this study, Vera Bruderer-125 
Rüeggers (Institute of Medical Microbiology, University of Zurich) for cultivation of the B. 126 
henselae strains, and Sabrina Traxel (Division of Infectious Diseases and Hospital 127 




[1] Zbinden R, Michael N, Sekulovski M, von Graevenitz A and Nadal D. Evaluation of 131 
commercial slides for detection of immunoglobulin G against Bartonella henselae by 132 
indirect immunofluorescence. Eur J Clin Microbiol Infect Dis 1997;9:648-52. 133 
[2] Zbinden R. Bartonella henselae-based indirect fluorescence assays are useful for 134 
diagnosis of cat scratch disease. J Clin Microbiol 1998;12:3741-2. 135 
[3] Otsuyama K, Tsuneoka H, Kondou K, Yanagihara M, Tokuda N, Shirasawa B, et al. 136 
Development of a highly specific IgM enzyme-linked immunosorbent assay for 137 
Bartonella henselae using refined N-lauroyl-sarcosine-insoluble proteins for 138 
serodiagnosis of cat scratch disease. J Clin Microbiol 2016;4:1058-64. 139 
[4] Goldenberger D, Zbinden R, Perschil I and Altwegg M. [Detection of Bartonella 140 
(Rochalimaea) henselae/B. quintana by polymerase chain reaction (PCR)]. Schweiz 141 
Med Wochenschr 1996;6:207-13. 142 
[5] Jost M, Latz A, Ballhorn W and Kempf VAJ. Development of a specific and sensitive 143 
enzyme-linked immunosorbent assay as an in vitro diagnostic tool for detection of 144 




Figure 1. (A-E) Comparison of Bartonella henselae-specific ELISA (A-C) and IFA (D-E) 148 
test results between PCR-positive CSD patients (n=25) and control subjects (n=23). The 149 
median is shown as a dark gray line across the gray box that represents the lower and upper 150 
quartiles. Whiskers extend to the maximum or minimum values within 1.5 times the 151 
interquartile range above and below the 3rd and 1st quartile, respectively. The dashed line 152 
represents the optimal cut-off of the test that maximizes the distance to the identity (diagonal) 153 
line in the ROC curve (Figure 1F) according to Youden J statistic using the “coords” function 154 
in R software environment (version 3.6.0). Differences in proportions (Fisher exact test) and 155 
medians (Mann-Whitney U test) were statistically significant for all tests between groups 156 
(p<0.01). (F) Receiver operating characteristics (ROC) curve of sensitivity vs. specificity for 157 
B. henselae-specific ELISA and IFA. Statistically significant area under the ROC curve 158 
(AUC) differences (DeLong's test): IgM-ELISA vs. IgG-ELISA, p<0.01; IgM-ELISA vs. 159 
IgM/IgG/IgA-ELISA, p=0.02; IgG-ELISA vs. IgM-IFA, p=0.02; IgG-ELISA vs. IgG-IFA, 160 
p=0.01. Abbreviations: AU, arbitrary units; AUC, area under the receiver operating 161 
characteristic curve; CSD, cat-scratch disease; ELISA, enzyme-linked immunosorbent assay; 162 
IFA, immunofluorescence assay; Ig, immunoglobulin; PCR, polymerase chain reaction; ROC, 163 




Supplementary Material 166 
Figures 167 
Figure S1. Western blot analysis of the prepared sarcosine-insoluble Bartonella henselae 168 
protein antigen. Lane a, marker; lane b, IgM-IFA- and IgG-IFA-positive sera derived from 169 
PCR-positive CSD patients; lane c, IFA-negative control sera. Molecular size markers (kDa) 170 
are indicated on the left. Serum samples were tested as previously described [3], with some 171 
modifications. Briefly, the antigen was diluted in the loading buffer Rotiâ-Load (Carl Roth, 172 
Karlsruhe, Germany). For separation we used a 4-12% Bis-Tris gel (Expedeon, San Diego, 173 
CA, USA) for SDS-PAGE with 2-MES (pH 7.3) (Sigma, Missouri, USA) as running buffer. 174 
The membranes were stained with Ponceau S (Sigma, Missouri, USA), while polyclonal goat 175 
anti-human polyvalent Igs (IgM, IgG, IgA)-peroxidase antibody (Sigma, Missouri, USA) was 176 
used as the antibody and Super Signal West Dura substrate (Thermo Fisher Scientific, 177 




Figure S2. Transformation from optical density (OD) to arbitrary unit (AU) separately for 181 
each ELISA. OD results of a dilution series of IgM-IFA- and IgG-IFA-positive sera were 182 










Table S1. Overview of diagnostic performances of Bartonella henselae-specific ELISAs in 186 
the literature. 187 
 188 
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Antigen:            
- Whole-cell antigen          + + +     + 
- N-lauroyl-sarcosine-insoluble protein + ("antigen IV")                     
- N-lauroyl-sarcosine-soluble protein       +               
- Water-insoluble protein   + ("fraction 24")                   
- Recombinant 17-kDa protein     +   +       +     
- GroEL     +                 
- Outer membrane protein 
 
                  +   
Samples with test criteria:            
- CSD-positive, n: 24 43 64 118 13 126 155 51 45 131 56 
  - PCR-positive, n 8* 10** – – – 126 155 51 – – – 
  - IFA-positive (IgG and/or IgM), n 24 33 64 118 13 – – – 25 131 – 
  - Skin test-positive, n – – – – – – – – – – 56 
- Controls, n: 85 16 87 88 34 126 244 56 86 10 57 
  - PCR-negative, n – – – – – – – 56 – – – 
  - IFA-negative, n 
 
85 16 87 88 34 – – – 86 10 – 
ELISA performance:            
- IgM:            
  - Sensitivity (%) 83 – 86 (17-kDa) 
98 (GroEL) 
– 100 56 32 65 – 94 73 
  - Specificity (%) 100 – 75 (17-kDa) 
45 (GroEL) 
– 97 98 98 91 – 99 95 
- IgG:            




96 – 36 45 – 71 86 18 




98 – 98 98 – 93 96 95 
IFA performance:            
- IgM:            
  - Sensitivity (%) 54 – – – – – – 53 – – – 
  - Specificity (%) – – – – – – – 93 – – – 
- IgG:            
  - Sensitivity (%) – – – – – – – – – – 93 
  - Specificity (%) 
 
– – – – – – – – – – 98 
*8 out of 24 IFA-positive CSD patients were also tested by PCR (lymph node, n=4; whole blood, n=4); **10 out of 43 CSD patients were tested by PCR (lymph node, n=10). Test characteristics and criteria for samples as in the current report are indicated in dark gray. 
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0.96 (0.80–0.99) 0.91 (0.73–0.98) 0.04 (0.01–0.30) 11.04 (2.93–41.60) 252.00 (21.30–2981.84) 
IgG-ELISA 
 
0.72 (0.52–0.86) 0.65 (0.45–0.81) 0.43 (0.21–0.86) 2.07 (1.12–3.81) 4.82 (1.42–16.40) 
IgM/IgG/IgA-ELISA 
 
0.76 (0.57–0.89) 0.78 (0.58–0.90) 0.31 (0.15–0.64) 3.50 (1.56–7.83) 11.40 (2.95–44.00) 
IgM-IFA 
 
0.88 (0.70–0.96) 1.00 (0.86–1.00) 0.12 (0.04–0.35) NA NA 
IgG-IFA 
 
0.84 (0.65–0.94) 1.00 (0.86–1.00) 0.16 (0.07–0.39) NA NA 
 192 
Abbreviations: CI, confidence interval; DOR, diagnostic odds ratio; LR-, negative likelihood ratio; LR+, positive likelihood ratio; NA, not available. 193 
 194 
